AzTrials
AzTrials

Urinary Bladder, NeurogenicPhase 3NCT01557244

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

A Phase 3 study testing Fesoterodine PR 4 mg, Fesoterodine PR 8 mg and Oxybutynin in people with Urinary Bladder, Neurogenic, run by Pfizer at 84 sites in 25 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of the study is to find out if the medicine fesoterodine is a useful treatment in children with bladder muscle overactivity caused by a neurological condition. Children will be aged 6 to 17 years old. Read more about this study

Who is it for?
Ages 6 to 17 years
Conditions the study is for
Urinary Bladder, Neurogenic
What is being tested?
Fesoterodine PR 4 mg, Fesoterodine PR 8 mg and Oxybutynin
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
181 participants
Where
84 sitesin 25 countries
Study dates
2 Jul 2012to 13 Feb 2020
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Subjects aged 6 to 17 years old
  • Subjects with stable neurological disease and neurogenic detrusor overactivity
  • Subjects using clean intermittent catheterization may participate

Who cannot join

  • Concomitant medications which may increase the risk to subjects or confound study results
  • Other medical conditions which may increase the risk to subjects or confound study results
  • Contraindications to the use of fesoterodine or oxybutynin

Trial locations and contacts

84 sites in 25 countries.

84 sites in 25 countries

United States18 sites
  • Children's Healthcare of Atlanta

    Atlanta, Georgia, 30342

  • Georgia Urology, P.A.

    Atlanta, Georgia, 30342

  • Judson L. Hawk Jr. M.D.

    Atlanta, Georgia, 30342

  • UNC Chapel Hill Memorial Hospital

    Chapel Hill, North Carolina, 27514

  • UNC Memorial Hospital Pediatric Clinic

    Chapel Hill, North Carolina, 27514

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229

  • Advanced Radiology

    East Providence, Rhode Island, 02914

  • Pharma Resource

    East Providence, Rhode Island, 02915

  • Cincinnati Children's Hospital Medical Center

    Liberty Township, Ohio, 45044

  • Loyola University Medical Center

    Maywood, Illinois, 60153

  • Loyola University Outpatient Center

    Maywood, Illinois, 60153

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin, 53226

  • Childrens Hospital of Orange County

    Orange, California, 92868

  • CHOC Children's Urology Center

    Orange, California, 92868

  • University Urological Associates, Inc

    Providence, Rhode Island, 02904

  • University Urological Associates, Inc.

    Providence, Rhode Island, 02905

  • Urological Associates of Southern Arizona

    Tucson, Arizona, 85715

  • The Iowa Clinic

    West Des Moines, Iowa, 50266

Other trials in United States

Japan13 sites
  • The University of Tokyo Hospital / Urology

    Bunkyo-ku, Tokyo, 113-8655

  • Chiba Children's Hospital

    Chiba, Chiba, Japan, 266-0007

  • Fukuoka Children's Hospital

    Fukuoka, Fukuoka, 813-0017

  • Osaka Medical Center and Research Institute for Maternal and Child Health

    Izumi-shi, Osaka, 594-1101

  • Hyogo prefectural Kobe Children's Hospital

    Kobe, Hyōgo, 650-0047

  • Dokkyo Medical University Koshigaya Hospital

    Koshigaya, Saitama, 343-8555

  • Shinshu University Hospital

    Matsumoto, Nagano, 3908621

  • Aichi Children's Health and Medical Center

    Ōbu, Aichi-ken, 474 8710

  • Hokkaido University Hospital

    Sapporo, Hokkaido, 060-8648

  • Dokkyo Medical University Hospital / Urology

    Shimotsuga-gun, Tochigi, 321 0293

  • Jichi Medical University Hospital

    Shimotsuke, Tochigi, 329 0498

  • Shizuoka Children's Hospital

    Shizuoka, Shizuoka, 420 8660

  • Kanagawa Children's Medical Center

    Yokohama, Kanagawa, 232-8555

Other trials in Japan

South Korea6 sites
  • Korea University Guro Hospital

    Seoul, Korea, 08308

  • Seoul National University Hospital

    Seoul, 03080

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722

  • ASAN Medical Center

    Seoul, 05505

  • Samsung Medical Center

    Seoul, 06351

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam-do, 50612

Other trials in South Korea

Italy5 sites
  • Azienda Ospedaliera G. Brotzu, Dipartimento di Medicina interna-

    Cagliari, 09134

  • Azienda Ospedaliera Universitaria Careggi

    Florence, 50139

  • IRCCS Ospedale Pediatrico Bambino Gesù

    Roma, 00165

  • I.R.C.C.S. - Ospedale "Casa Sollievo della Sofferenza" - Dipartimento Scienze Chirurgiche

    San Giovanni Rotondo, Foggia, 71013

  • ULSS 6 VICENZA - Ospedale San Bortolo di Vicenza

    Vicenza, 36100

Other trials in Italy

Russia5 sites
  • Kazan State Medical University

    Kazan', Tatarstan Republic, 420012

  • Children's Republican Clinical Hospital, Department of Pediatric Surgery

    Kazan', 420138

  • FGBNU Scientific center of children health

    Moscow, Russian Federation, 119991

  • Scientific Research Institute of Urology named after N.A.Lopatkin of the Hertsen Federal Medical

    Moscow, 105425

  • SSS - Research Clinical Institute of Pediatrics n.a. Academician Y.E.Veltishchev GBOU VPO

    Moscow, 125412

Other trials in Russia

Spain5 sites
  • Hospital Sant Joan de Deu

    Esplugues de Llobregat, Barcelona, 08950

  • Hospital General Universitario Gregorio Marañon

    Madrid, 28007

  • Hospital Infantil Universitario Niño Jesus

    Madrid, 28009

  • Hospital Regional Universitario Carlos Haya

    Málaga, 29011

  • Hospital Universitari i Politecnic La Fe

    Valencia, 46026

Other trials in Spain

Turkey (Türkiye)4 sites
  • Ankara Universitesi Tip Fakultesi Ibni Sina Hastanesi

    Ankara, 06100

  • Hacettepe Universitesi Tip Fakultesi Uroloji Anabilim Dali

    Ankara, 06100

  • Istanbul Universitesi Istanbul Tip Fakultesi

    Istanbul, 34390

  • Necmettin Erbakan Universitesi Meram Tip Fakultesi

    Konya, Konya / Turkey, 42080

Other trials in Turkey (Türkiye)

France3 sites
  • Centre d'Investigation Clinique

    Bron, 69677

  • Groupement Hospitalier Est - Hopital Femme Mere Enfant

    Bron, 69677

  • Hôpitaux Pédiatriques de Nice CHU-Lenval

    Nice, 06200

Other trials in France

United Kingdom3 sites
  • Leicester Royal Infirmary

    Leicester, LE1 5WW

  • Alder Hey Children's Hospital

    Liverpool, L12 2AP

  • Sheffield Children's NHS Foundation Trust

    Sheffield, S10 2TH

Other trials in United Kingdom

Belgium2 sites
  • Hôpital Universitaire des Enfants Reine Fabiola

    Brussels, Brussels Capital, 1020

  • Universitair Ziekenhuis Antwerpen, Urologie

    Edegem, Antwerpen, 2650

Other trials in Belgium

Greece2 sites
  • University General Hospital of Larisa/ Urology Department

    Larissa, 41110

  • Aristotle University of Thessaloniki

    Thessaloniki, 56429

Other trials in Greece

Lithuania2 sites
  • Hospital of Lithuanian University of Health Sciences Kaunas klinikos

    Kaunas, LT-50161

  • Children's Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos

    Vilnius, LT-08406

Other trials in Lithuania

Malaysia2 sites
  • Hospital Selayang

    Batu Caves, Selangor, 68100

  • Hospital Kuala Lumpur

    Kuala Lumpur, 50586

Other trials in Malaysia

Poland2 sites
  • Klinika Chorob Nerek i Nadcisnienia Dzieci i Mlodziezy

    Gdansk, 80-952

  • Specjalistyczny Gabinet Lekarski Paweł Kroll

    Poznan, 61-512

Other trials in Poland

Slovakia2 sites
  • J. BREZA MEDICAL s.r.o.

    Bratislava, 831 01

  • Narodny ustav detskych chorob

    Bratislava, 833 40

Other trials in Slovakia

Canada1 site
  • Centre hospitalier universitaire (CHU) Sainte-Justine

    Montreal, Quebec, H3T 1C5

Other trials in Canada

Estonia1 site
  • Tallinn Children's Hospital

    Tallinn, 13419

Other trials in Estonia

Finland1 site
  • Tampere University Hospital

    Tampere, 33520

Other trials in Finland

Germany1 site
  • Kliniken Maria Hilf GmbH

    Mönchengladbach, North Rhine-Westphalia, 41063

Other trials in Germany

India1 site
  • Department of Pediatrics, Christian Medical College and Hospital

    Ludhiana, Punjab, 141 008

Other trials in India

Philippines1 site
  • Philippine Children's Medical Center

    Quezon City, NCR, 1100

Other trials in Philippines

South Africa1 site
  • Red Cross Children's Hospital

    Cape Town, Western Cape, 7700

Other trials in South Africa

Sweden1 site
  • Akademiska barnsjukhuset

    Uppsala, 751 85

Other trials in Sweden

Switzerland1 site
  • Universitäts-Kinderspital beider Basel

    Basel, 4031

Other trials in Switzerland

Taiwan1 site
  • National Cheng Kung University Hospital

    Tainan, 704

Other trials in Taiwan

About this study

Official title: A 24-WEEK RANDOMIZED, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY)

The objective of the study is to find out if the medicine fesoterodine is a useful treatment in children with bladder muscle overactivity caused by a neurological condition. Children will be aged 6 to 17 years old. This is done by finding out how well it works, what the body does to fesoterodine, what side effects are experienced and the safety of fesoterodine. It will be compared with the medicine oxybutynin, which is already available for treating the condition.

Being tested
Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin, Fesoterodine PR, Fesoterodine BIC 2 mg
Keywords
neurogenic detrusor overactivity, neurogenic bladder, neuropathic bladder, neurologic disease, fesoterodine
Medical subject headings
Urinary Bladder, Neurogenic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fesoterodine PR 4 mgDrug

    Fesoterodine 4 mg tablet once daily for 24 weeks

  • Fesoterodine PR 8 mgDrug

    Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.

  • Fesoterodine PR 8 mgDrug

    Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.

  • OxybutyninDrug

    Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.

  • Fesoterodine PRDrug

    Also called Safety extension phase

    Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.

  • Fesoterodine BIC 2 mgDrug

    Fesoterodine BIC 2 mg tablet once daily for 24 weeks.

  • Fesoterodine BIC 4 mgDrug

    Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.

Study groups in NCT01557244
Study groupRoleWhat they receive
Fesoterodine PR 4 mgExperimentalFesoterodine PR 4 mg for 12 weeks in active comparator period, followed by 12 weeks in safety extension period
Receives: Drug: Fesoterodine PR 4 mg
Fesoterodine PR 8 mgExperimentalFesoterodine 8 mg for first week followed by 11 weeks at 8 mg in active control period, followed by 12 weeks in safety extension period.
Receives: Drug: Fesoterodine PR 8 mg
OxybutyninActive comparatorOxybutynin
Receives: Drug: Oxybutynin; Drug: Fesoterodine PR
Fesoterodine BIC 2 mgExperimentalFesoterodine BIC 2 mg for 12 weeks in efficicay period, followed by 12 weeks in safety extension period.
Receives: Drug: Fesoterodine BIC 2 mg
Fesoterodine BIC 4 mgExperimentalFesoterodine BIC 4 mg for first week followed by 11 weeks at 8 mg in the efficacy period, followed by 12 weeks in safety extension period.
Receives: Drug: Fesoterodine BIC 4 mg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Maximum Cystometric Bladder Capacity at Week 12: Active Comparator Phase/Efficacy Phase

    Maximum cystometric bladder capacity (in milliliter) was defined as maximal tolerable cystometric capacity, until voiding or leaking begins or at a pressure of >=40 centimeter (cm) water (H2O).

    Measured: Baseline, Week 12

Secondary outcomes (47)
  1. Change From Baseline in Detrusor Pressure at Maximum Bladder Capacity at Week 12: Active Comparator Phase/Efficacy Phase

    Detrusor pressure (in cm H2O) at maximum urinary bladder capacity was measured using urodynamic testing.

    Measured: Baseline, Week 12

  2. Number of Participants With Shift From Baseline at Week 12 in Involuntary Detrusor Contractions (IDC): Active Comparator Phase/Efficacy Phase

    In this outcome measure, shift data have been reported using 4 categories: (1) number of participants who did not have IDC at Baseline and at Week 12, (2) number of participants who did not have IDC at Baseline but had IDC at Week 12, (3) number of participants who had IDC at Baseline but no IDC at Week 12, and (4) number of participants who had IDC at Baseline and at Week 12.

    Measured: Baseline, Week 12

  3. Change From Baseline in Bladder Volume at First Involuntary Detrusor Contraction (IDC) at Week 12: Active Comparator Phase/Efficacy Phase

    Bladder volume (in milliliter) at first IDC was measured using urodynamic testing.

    Measured: Baseline, Week 12

  4. Change From Baseline in Bladder Compliance at Week 12: Active Comparator Phase/Efficacy Phase

    Bladder compliance was defined as change in bladder volume in milliliter (mL) divided by change in bladder pressure in cm H2O (during the same time when change in bladder volume was estimated).

    Measured: Baseline, Week 12

  5. Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase

    The mean number of micturitions per 24 hours were calculated as the total number of micturitions divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with >0 micturitions at Baseline.

    Measured: Baseline, Week 12

  6. Change From Baseline in Mean Number of Catheterizations Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase

    The mean number of catheterizations per 24 hours were calculated as the total number of catheterizations divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on; even if it was not a full 24 hours period. This outcome measure was only calculated for participants with >0 catheterizations at Baseline.

    Measured: Baseline, Week 12

  7. Change From Baseline in Mean Number of Micturitions or Catheterizations Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase

    The mean number of micturitions or catheterizations combined per 24 hours were calculated as the total number of micturitions and catheterizations combined divided by the total number of diary days collected at the assessment point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hour (hrs) period. This outcome was evaluated in those participants who had micturitions or catheterizations >0 at Baseline.

    Measured: Baseline, Week 12

  8. Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase

    The mean number of incontinence episodes per 24 hours were calculated as the total number of incontinence episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hours period. This outcome measure was only calculated for participants with >0 incontinence episodes at Baseline.

    Measured: Baseline, Week 12

  9. Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12: Active Comparator Phase/Efficacy Phase

    The mean number of urgency episodes per 24 hours were calculated as the total number of urgency episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed; even if it was not a full 24 hours period. Urgency episodes were defined as urgency marked as 'yes' in the diary. This outcome measure was only calculated for participants with >0 urgency episodes at Baseline.

    Measured: Baseline, Week 12

  10. Change From Baseline in Mean Volume Voided Per Micturition at Week 12: Active Comparator Phase/Efficacy Phase

    The mean voided volume per micturition was calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume greater than 0.

    Measured: Baseline, Week 12

  11. Change From Baseline in Mean Volume Voided Per Catheterization at Week 12: Active Comparator Phase/Efficacy Phase

    The mean volume per catheterization was calculated as sum of voided volume divided by the total number of catheterization, with a recorded voided volume greater than 0.

    Measured: Baseline, Week 12

  12. Change From Baseline in Mean Volume Voided Per Micturition or Catheterization at Week 12: Active Comparator Phase/Efficacy Phase

    The mean voided volume per micturition or catheterization was calculated as sum of voided volume divided by the total number of micturition or catheterization episodes with a recorded voided volume greater than 0. This outcome was evaluated in those participants who had micturitions or catheterizations >0 at Baseline.

    Measured: Baseline, Week 12

  13. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Active Comparator Phase/Efficacy Phase

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both all serious and non-serious adverse events.

    Measured: Baseline up to Week 12

  14. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Safety Extension Phase

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both all serious and non-serious adverse events.

    Measured: Week 12 up to Week 26 (including 2 weeks of follow up after last dose)

  15. Change From Baseline in Visual Acuity at Week 12: Active Comparator Phase/Efficacy Phase

    Visual acuity (VA) was assessed using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA/Snellen ratio = distance between the chart and participant, divided by the distance at which participant was able to see or read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure data have been reported for right and left eye separately.

    Measured: Baseline, Week 12

  16. Change From Baseline in Visual Acuity at Week 24: Safety Extension Phase

    VA was assessed using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA/Snellen ratio = distance between the chart and participant, divided by the distance at which participant was able to see or read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure data have been reported for right and left eye separately.

    Measured: Baseline, Week 24

  17. Change From Baseline in Visual Accommodation at Week 12: Active Comparator Phase/Efficacy Phase

    The visual accommodation was the distance for each eye at which vision became blurred and was calculated as the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately.

    Measured: Baseline, Week 12

  18. Change From Baseline in Visual Accommodation at Week 24: Safety Extension Phase

    The visual accommodation is the distance for each eye at which vision became blurred and was calculated as the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately.

    Measured: Baseline, Week 24

  19. Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 12: Active Comparator Phase/Efficacy Phase

    CBCL: 120 items questionnaire answered by parent/caregiver of child to assess a child's behavioral, emotional problems. Scale for each item: 0= not true, 1= somewhat/sometimes true, 2= very true/often true. Out of 120 items, 103 were categorized into 8 domains; aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems=anxious/depressed + withdrawn + somatic complaints; Externalizing problems=rule-breaking + aggressive behavior. Total problems=8 domains + other 17 items. Raw scores for each domain, summary and total problems=sum of scores of related items. Using Assessment Data Manager (ADM) tool raw scores transformed/derived into standard T-scores, range: each domain=50 to 100, internalizing problems=34 to 100, externalizing problems=33 to 100, total problems=24 to 100. Lower T-score for each 8 domains, 2 summary and total problems scores=better outcomes.

    Measured: Baseline, Week 12

  20. Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 24: Safety Extension Phase

    CBCL: 120 items questionnaire answered by parent/caregiver of child to assess a child's behavioral, emotional problems. Scale for each item: 0= not true, 1= somewhat/sometimes true, 2= very true/often true. Out of 120 items, 103 were categorized into 8 domains; aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems=anxious/depressed + withdrawn + somatic complaints; Externalizing problems=rule-breaking + aggressive behavior. Total problems=8 domains + other 17 items. Raw scores for each domain, summary and total problems=sum of scores of related items. Using Assessment Data Manager (ADM) tool raw scores transformed/derived into standard T-scores, range: each domain=50 to 100, internalizing problems=34 to 100, externalizing problems=33 to 100, total problems=24 to 100. Lower T-score for each 8 domains, 2 summary and total problems scores=better outcomes.

    Measured: Baseline, Week 24

  21. Change From Baseline in Child Behavior Checklist Total Score (Raw Score) at Week 12: Active Comparator Phase/Efficacy Phase

    CBCL: It consisted of 120 items on behavior and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0= not true, 1= somewhat/sometimes true, 2= very/often true. 103 items were classified in 8 domains: aggressive behavior: total score range (TSR)= 0 to 36, anxious/depressed: TSR= 0 to 26, attention problems: TSR= 0 to 20, rule-breaking behavior: TSR= 0 to 34, social problems: TSR= 0 to 22, somatic complaints: TSR= 0 to 22, thought problems: TSR= 0 to 30, withdrawn (TSR)= 0 to 16. Rule-breaking and aggressive behavior summarized to externalizing problems with a TSR= 0 to 70. Anxious/depressed, withdrawn, somatic complaints summarized to internalizing problems with a TSR= 0 to 64. All 103 items of 8 domains and other 17 remaining items were combined to give total problems TSR = 0 to 240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary and total problems= better outcomes.

    Measured: Baseline, Week 12

  22. Change From Baseline in Child Behavior Checklist Total Score (Raw Score) at Week 24: Safety Extension Phase

    CBCL: It consisted of 120 items on behavior and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0= not true, 1= somewhat/sometimes true, 2= very/often true. 103 items were classified in 8 domains: aggressive behavior: total score range (TSR)= 0 to 36, anxious/depressed: TSR= 0 to 26, attention problems: TSR= 0 to 20, rule-breaking behavior: TSR= 0 to 34, social problems: TSR= 0 to 22, somatic complaints: TSR= 0 to 22, thought problems: TSR= 0 to 30, withdrawn (TSR)= 0 to 16. Rule-breaking and aggressive behavior summarized to externalizing problems with a TSR= 0 to 70. Anxious/depressed, withdrawn, somatic complaints summarized to internalizing problems with a TSR= 0 to 64. All 103 items of 8 domains and other 17 remaining items were combined to give total problems TSR = 0 to 240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary and total problems= better outcomes.

    Measured: Baseline, Week 24

  23. Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.

    Measured: Baseline, Week 12

  24. Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.

    Measured: Baseline, Week 24

  25. Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.

    Measured: Baseline, Week 12

  26. Change From Baseline in Time to Completion Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. In this outcome measure participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability.

    Measured: Baseline, Week 24

  27. Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.

    Measured: Baseline, Week 12

  28. Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.

    Measured: Baseline, Week 24

  29. Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.

    Measured: Baseline, Week 12

  30. Change From Baseline in Number of Pegs Dropped Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs dropped while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.

    Measured: Baseline, Week 24

  31. Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.

    Measured: Baseline, Week 12

  32. Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 10 Pegs Group at Week 24: Safety Extension Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.

    Measured: Baseline, Week 24

  33. Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 12: Active Comparator Phase/Efficacy Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.

    Measured: Baseline, Week 12

  34. Change From Baseline in Number of Pegs Placed Correctly Assessment of Grooved Pegboard Test, 25 Pegs Group at Week 24: Safety Extension Phase

    The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. It consisted of a small board of 25 holes with randomly positioned slots. Pegs with a key along one side must be rotated to match the hole before they can be inserted. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). In this outcome measure number of pegs placed correctly while putting in the holes were measured. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand.

    Measured: Baseline, Week 24

  35. Number of Participants Meeting Pre-defined Criteria for Vital Signs Values From Baseline Through Week 12: Active Comparator/Efficacy Phase

    Pre-defined criteria for vital signs: 1) a) systolic blood pressure (SBP) of <90 millimeter of mercury (mmHg), b) change >=30 mmHg increase, c) change >=30 mmHg decrease; 2) a) diastolic blood pressure (DBP) of <50 mmHg, b) change >=20 mmHg increase, c) change >=20 mmHg decrease; 3) a) pulse rate value of <40 beats per minute (bpm), b) pulse rate value >120 bpm.

    Measured: Baseline up to Week 12

  36. Number of Participants Meeting Pre-defined Criteria for Vital Signs Values From Baseline Through Week 24: Safety Extension Phase

    Pre-defined criteria for vital signs: 1) a) systolic blood pressure (SBP) of <90 millimeter of mercury (mmHg), b) change >=30 mmHg increase, c) change >=30 mmHg decrease; 2) a) diastolic blood pressure (DBP) of <50 mmHg, b) change >=20 mmHg increase, c) change >=20 mmHg decrease; 3) a) pulse rate value of <40 beats per minute (bpm), b) pulse rate value >120 bpm.

    Measured: Baseline up to Week 24

  37. Number of Participants With Clinically Significant Urinary Tract Infections (UTI): Active Comparator/Efficacy Phase

    Clinically significant UTI, counted as an adverse event was defined as: positive urine culture with a uropathogen (defined as >=10^5 colony forming unit per milliliter [CFU/mL]) and the presence of symptoms, or pyuria (defined as >50 white blood cells [WBC] per high-pass filter [hpf]) and the presence of symptoms, or positive urine culture with a uropathogen (defined as >=10^5 CFU/mL) with or without symptoms in a participant with a documented history of vesicoureteral reflux (VUR).

    Measured: Week 1 up to Week 12

  38. Number of Participants With Clinically Significant Urinary Tract Infections (UTI): Safety Extension Phase

    Clinically significant UTI, counted as an adverse event was defined as: positive urine culture with a uropathogen (defined as >=10^5 CFU/mL) and the presence of symptoms, or pyuria (defined as >50 WBC per hpf and the presence of symptoms, or positive urine culture with a uropathogen (defined as >=10^5 CFU/mL) with or without symptoms in a participants with a documented history of VUR.

    Measured: Week 12 up to Week 26

  39. Number of Participants With Clinical Laboratory Abnormalities: Active Comparator/Efficacy Phase

    Hematology: hemoglobin, hematocrit, erythrocytes <0.8*lower limit of normal (LLN), platelets<0.5*LLN>1.75*upper limit of normal (ULN), leukocytes <0.6*LLN>1.5*ULN, lymphocytes, neutrophils, <0.8*LLN >1.2*ULN, basophils, eosinophils, monocytes monocytes/leukocytes >1.2*ULN. Clinical chemistry: bilirubin, direct, bilirubin >1.5*ULN, aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase>3.0*ULN, protein, albumin, phosphate <0.8*LLN >1.2*ULN, blood urea nitrogen, creatinine >1.3*ULN, urate >1.2*ULN, sodium<0.95*LLN>1.05*ULN, potassium, chloride, calcium bicarbonate<0.9*LLN>1.1*ULN, glucose<0.6*LLN>1.5*ULN, creatine kinase >2.0*ULN. Urinalysis: specific gravity <1.003>1.030, pH <4.5>8, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite, >=1, urine erythrocytes, urine leukocytes >=20, epithelial cells >=6, bacteria >20.

    Measured: Week 1 up to Week 12

  40. Number of Participants With Clinical Laboratory Abnormalities: Safety Extension Phase

    Hematology: hemoglobin, hematocrit, erythrocytes <0.8*lower limit of normal (LLN), platelets<0.5*LLN>1.75*upper limit of normal (ULN), leukocytes <0.6*LLN>1.5*ULN, lymphocytes, neutrophils, <0.8*LLN >1.2*ULN, basophils, eosinophils, monocytes monocytes/leukocytes >1.2*ULN. Clinical chemistry: bilirubin, direct, bilirubin >1.5*ULN, aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase>3.0*ULN, protein, albumin, phosphate <0.8*LLN >1.2*ULN, blood urea nitrogen, creatinine >1.3*ULN, urate >1.2*ULN, sodium<0.95*LLN>1.05*ULN, potassium, chloride, calcium bicarbonate<0.9*LLN>1.1*ULN, glucose<0.6*LLN>1.5*ULN, creatine kinase >2.0*ULN. Urinalysis: specific gravity <1.003>1.030, pH <4.5>8, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite, >=1, urine erythrocytes, urine leukocytes >=20, epithelial cells >=6, bacteria >20.

    Measured: Week 12 up to Week 26

  41. Change From Baseline in Post-Void Residual (PVR) Volume at Weeks 4, 12: Active Comparator Phase/Efficacy Phase

    Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had >1 UTI during the study.

    Measured: Baseline, Week 4, 12

  42. Change From Baseline in Post-Void Residual Volume at Week 24: Safety Extension Phase

    Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had >1 UTI during the study.

    Measured: Baseline, Week 24

  43. Number of Participants With Clinically Relevant Changes in Physical Examination Findings From Baseline to Week 12: Active Comparator/Efficacy Phase

    Physical examination included assessment of the general appearance and the skin, head, ears, eyes, nose, mouth, throat, respiratory, cardiovascular, gastrointestinal, musculoskeletal and neurological systems. Clinically relevant changes in physical findings were assessed by the investigator.

    Measured: Baseline up to Week 12

  44. Number of Participants With Clinically Relevant Changes in Physical Examination Findings From Baseline to Week 24: Safety Extension Phase

    Physical examination included assessment of the general appearance and the skin, head, ears, eyes, nose, mouth, throat, respiratory, cardiovascular, gastrointestinal, musculoskeletal and neurological systems. Clinically relevant changes in physical findings were assessed by the investigator.

    Measured: Baseline up to Week 24

  45. Absorption Rate Constant (Ka) of Fesoterodine

    Absorption rate constant is used to determine rate at which drug is entering into body. Pharmacokinetic (PK) analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.

    Measured: Week 4, Day 1: pre-dose (when dose administered at clinic) or if dose taken at home up to 3 hours before coming to the clinic, sampling just after arrival at clinic, 5 hours post-dose, 8-10 hours post-dose (if participants remained at clinic)

  46. Apparent Oral Clearance (CL/F) of Fesoterodine

    Clearance determines the rate at which a drug is metabolized or eliminated by normal biological processes. PK analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.

    Measured: Week 4, Day 1: pre-dose (when dose administered at clinic) or if dose taken at home up to 3 hours before coming to the clinic, sampling just after arrival at clinic, 5 hours post-dose, 8-10 hours post-dose (if participants remained at clinic)

  47. Volume of Distribution (Vd) of Fesoterodine

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. PK analysis was not done separately for each dose of fesoterodine in respective cohorts and were combined for PK analysis using PK modelling approach.

    Measured: Week 4, Day 1: pre-dose (when dose administered at clinic) or if dose taken at home up to 3 hours before coming to the clinic, sampling just after arrival at clinic, 5 hours post-dose, 8-10 hours post-dose (if participants remained at clinic)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Mar 2012 (estimated)
  2. Study start2 Jul 2012
  3. Primary completion7 Nov 2019
  4. Study completion13 Feb 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
181 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01557244
Sponsor's protocol ID
A0221047
Other IDs
2010-022475-55
Status last verified
Dec 2020
First submitted
15 Mar 2012
Last updated
2 Feb 2021
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Sano Y, Shoji S, Shahin M, Sweeney K, Darekar A, Malhotra BK. Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity. Eur J Drug Metab Pharmacokinet. 2023 May;48(3):257-269. doi: 10.1007/s13318-023-00818-8. Epub 2023 Mar 9.

    PubMed 36892754
  • Kitta T, Darekar A, Malhotra B, Shahin MH, Jones P, Lindsay M, Mallen S, Nieto A, Crook TJ. Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study. J Pediatr Urol. 2023 Apr;19(2):175.e1-175.e10. doi: 10.1016/j.jpurol.2022.11.020. Epub 2022 Nov 29.

    PubMed 36504158

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Fesoterodine PR 4 mg, Fesoterodine PR 8 mg and Oxybutynin in people with Urinary Bladder, Neurogenic, run by Pfizer at 84 sites in 25 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 84 sites in United States, Japan, South Korea, Italy, Russia and 20 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Feb 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Maximum Cystometric Bladder Capacity at Week 12: Active Comparator Phase/Efficacy Phase (time frame: Baseline, Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01557244, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in